INOVIO PHARMACEUTICALS, INC. Pre-Tax Income
INOVIO PHARMACEUTICALS, INC. (INO) reported Pre-Tax Income of -$84.95 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-12
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2020-12-31 was -$22.42M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2020-09-30 was $20.93M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2020-06-30 was -$128.27M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2020-03-31 was -$33.14M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$84.95M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$107.25M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$135.12M.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$277.65M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$84.95M 10-K · filed 2026-03-12 | |||
| 2024-12-31 | -$107.25M 10-K · filed 2026-03-12 | |||
| 2023-12-31 | -$135.12M 10-K · filed 2025-03-18 | |||
| 2022-12-31 | -$277.65M 10-K · filed 2024-03-06 | |||
| 2021-12-31 | -$303.22M 10-K · filed 2024-03-06 | |||
| 2020-12-31 | -$22.42M 10-K · filed 2021-03-01 | -$1.48M derived: sum of 2 quarters · filed 2021-03-01 | -$129.75M derived: sum of 3 quarters · filed 2021-03-01 | -$162.89M 10-K · filed 2023-03-01 |
| 2020-09-30 | $20.93M 10-K · filed 2021-03-01 | -$107.34M derived: sum of 2 quarters · filed 2021-03-01 | -$140.48M derived: sum of 3 quarters · filed 2021-03-01 | -$178.71M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | -$128.27M 10-K · filed 2021-03-01 | -$161.41M derived: sum of 2 quarters · filed 2021-03-01 | -$199.64M derived: sum of 3 quarters · filed 2021-03-01 | -$223.18M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | -$33.14M 10-K · filed 2021-03-01 | -$71.37M derived: sum of 2 quarters · filed 2021-03-01 | -$94.91M derived: sum of 3 quarters · filed 2021-03-01 | -$124.59M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | -$38.24M 10-K · filed 2021-03-01 | -$61.77M derived: sum of 2 quarters · filed 2021-03-01 | -$91.46M derived: sum of 3 quarters · filed 2021-03-01 | -$120.81M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$23.54M 10-K · filed 2021-03-01 | -$53.22M derived: sum of 2 quarters · filed 2021-03-01 | -$82.57M 10-Q · filed 2019-11-12 | -$115.54M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$29.69M 10-K · filed 2021-03-01 | -$59.04M 10-Q · filed 2019-08-08 | -$92.00M derived: sum of 3 quarters · filed 2021-03-01 | -$117.02M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$29.35M 10-K · filed 2021-03-01 | -$62.31M derived: sum of 2 quarters · filed 2021-03-01 | -$87.33M derived: sum of 3 quarters · filed 2021-03-01 | -$93.97M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$32.96M 10-K · filed 2020-03-12 | -$57.98M derived: sum of 2 quarters · filed 2020-03-12 | -$64.62M derived: sum of 3 quarters · filed 2020-03-12 | -$94.80M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$25.02M 10-K · filed 2020-03-12 | -$31.65M derived: sum of 2 quarters · filed 2020-03-12 | -$61.84M 10-Q · filed 2019-11-12 | -$83.34M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$6.64M 10-K · filed 2020-03-12 | -$36.82M 10-Q · filed 2019-08-08 | -$58.33M derived: sum of 3 quarters · filed 2020-03-12 | -$92.46M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$30.18M 10-K · filed 2020-03-12 | -$51.69M derived: sum of 2 quarters · filed 2020-03-12 | -$85.82M derived: sum of 3 quarters · filed 2020-03-12 | -$95.30M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$21.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$55.64M derived: sum of 2 quarters · filed 2020-03-12 | -$65.12M derived: sum of 3 quarters · filed 2020-03-12 | -$88.21M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$34.13M 10-Q · filed 2018-11-08 | -$43.61M derived: sum of 2 quarters · filed 2018-11-08 | -$66.70M 10-Q · filed 2018-11-08 | -$92.93M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | -$9.48M 10-Q · filed 2018-08-07 | -$32.57M 10-Q · filed 2018-08-07 | -$58.80M derived: sum of 3 quarters · filed 2018-08-07 | -$79.56M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | -$23.09M 10-Q · filed 2018-05-09 | -$49.32M derived: sum of 2 quarters · filed 2018-05-09 | -$70.08M derived: sum of 3 quarters · filed 2018-05-09 | -$88.78M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | -$26.23M 10-K · filed 2017-03-15 | -$46.99M derived: sum of 2 quarters · filed 2017-03-15 | -$65.70M derived: sum of 3 quarters · filed 2017-03-15 | -$73.74M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$20.76M 10-K · filed 2017-03-15 | -$39.46M derived: sum of 2 quarters · filed 2017-03-15 | -$47.51M 10-Q · filed 2016-11-09 | -$65.77M derived: sum of 4 quarters · filed 2017-03-15 |
| 2016-06-30 | -$18.70M 10-K · filed 2017-03-15 | -$26.75M derived: sum of 2 quarters · filed 2017-03-15 | -$45.01M derived: sum of 3 quarters · filed 2017-03-15 | -$41.20M derived: sum of 4 quarters · filed 2017-03-15 |
| 2016-03-31 | -$8.04M 10-K · filed 2017-03-15 | -$26.30M derived: sum of 2 quarters · filed 2017-03-15 | -$22.50M derived: sum of 3 quarters · filed 2017-03-15 | -$28.66M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-12-31 | -$18.26M 10-K · filed 2017-03-15 | -$14.46M derived: sum of 2 quarters · filed 2017-03-15 | -$20.62M derived: sum of 3 quarters · filed 2017-03-15 | -$31.20M 10-K · filed 2018-03-14 |
| 2015-09-30 | $3.81M 10-K · filed 2017-03-15 | -$2.36M derived: sum of 2 quarters · filed 2017-03-15 | -$12.94M 10-Q · filed 2016-11-09 | -$20.35M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$6.16M 10-K · filed 2017-03-15 | -$16.75M derived: sum of 2 quarters · filed 2017-03-15 | -$24.16M derived: sum of 3 quarters · filed 2017-03-15 | -$31.34M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$10.58M 10-K · filed 2017-03-15 | -$18.00M derived: sum of 2 quarters · filed 2017-03-15 | -$25.17M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2014-12-31 | -$7.41M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$14.59M derived: sum of 2 quarters · filed 2017-03-15 | -$36.14M 10-K · filed 2017-03-15 | |
| 2014-09-30 | -$7.18M 10-Q · filed 2015-11-09 | -$28.73M 10-Q · filed 2015-11-09 | ||
| 2013-12-31 | -$66.08M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |